Conference Reports for NATAP
Back
 
9th Intl Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Sydney, Australia, July 19-21 2007
Dyslipidemia & Body Changes in Vertically Infected Children & Youth on PI ART: preliminary results of PACTG 1045
- (08/21/07)
 
Report from the 9th Intenational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sydney, Australia. July 19-21, 2007
- Written by Mike Dube - (08/16/07)
 
Lack of metabolic abnormalities and mitochondrial toxicity with enfuvirtide (T-20): a double-blind, placebo-controlled, crossover study with random sequence assignation in healthy adult volunteers
- (08/14/07)
 
Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals?
- (08/13/07)
 
Lack of Association between Antiretroviral Therapy and Predictors of Endothelial Function and Cardiovascular Disease (CVD) Risk Among HIV-Infected Persons on Long-Term HAART pioglitazone increased limb fat, exercise reduced limb fat
- (08/13/07)
 
Pioglitazone ± exercise training reduces liver lipid content and improves insulin sensitivity in HIV with impaired glucose tolerance; pioglitazone increased limb fat, exercise reduced limb fat
- (08/09/07)
 
Effects of tipranavir/r in comparison with lopinavir/r on changes in body composition and metabolic parameters in ARV-naive patients over 48 weeks
- (08/06/07)
 
Effects of alternate treatment protocols (discontinuation vs viral suppression) on the incidence of electrocardiographic abnormalities among HIV-infected adults in the SMART trial
- (08/06/07)
 
Racial Differences in Long-Term Changes in Metabolic and Body Composition Parameters in Antiretroviral Naive Persons Initiating HAART: Results of the CPCRA 061 Metabolic Study
- (08/06/07)
 
Zidovudine/lamivudine persistently contributes to peripheral insulin resistance by a body composition-independent mechanism demonstrated by repeated clamp studies during 2 years of first line ART with zidovudine/lamivudine/lopinavir/r
- (08/06/07)
 
Effects of 4 weeks of atazanavir, lopinavir/ritonavir, or placebo on endothelial function and insulin sensitivity in healthy men
- (07/20/07)
 
Relationship of body composition, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects: lipoatrophy associated with endothelial dysfunction
- (07/20/07)
 
Lack of evidence of Metabolic Abnormalities and Mitochondrial Toxicity with Enfuvertide: a double-blind, placebo-controlled, cross-over study with random sequence assignation in healthy adult volunteers
- (07/20/07)
 
HIV, ART & Endothelial Dysfunction
- (07/20/07)
 
Nevirapine Increases High Density Lipoprotein-Cholesterol (HDL-C) by Stimulation of Apolipoprotein AI Synthesis
- (07/19/07)
 
Nevirapine Hypersensitivity is Different for Treatment-Experienced
- (07/19/07)
 
TH9507, Growth Hormone Releasing Factor
- (07/19/07)